BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spencer CN, Mcquade JL, Gopalakrishnan V, Mcculloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau P, Harris AL, Jamal MA, Baruch EN, Perez-guijarro E, Day C, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 2021;374:1632-40. [DOI: 10.1126/science.aaz7015] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 91.0] [Reference Citation Analysis]
Number Citing Articles
1 Pereira MS, Kriegel MA. Evolving concepts of host–pathobiont interactions in autoimmunity. Current Opinion in Immunology 2023;80:102265. [DOI: 10.1016/j.coi.2022.102265] [Reference Citation Analysis]
2 Zidane M, Theurich S, Schlaak M. Malignes Melanom und Adipositas: eine Übersichtsarbeit. Adipositas - Ursachen, Folgeerkrankungen, Therapie 2022;16:220-227. [DOI: 10.1055/a-1849-6722] [Reference Citation Analysis]
3 Lin N, Dai T, Zhou J, Huang H, Yun H, Ding Z, Ma X. Evaluation of the nutritional index and immunological function of a fermented vegetable for esophageal cancer patients undergoing immunotherapy plus chemotherapy: A randomized controlled trial. Journal of Functional Foods 2022;99:105350. [DOI: 10.1016/j.jff.2022.105350] [Reference Citation Analysis]
4 Dong Z. Highlights of recent cancer research. Holist Integ Oncol 2022;1:2. [DOI: 10.1007/s44178-022-00003-y] [Reference Citation Analysis]
5 Wu Q, Gao Z, Yu X, Wang P. Dietary regulation in health and disease. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-01104-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Villemin C, Six A, Neville BA, Lawley TD, Robinson MJ, Bakdash G. The heightened importance of the microbiome in cancer immunotherapy. Trends in Immunology 2022. [DOI: 10.1016/j.it.2022.11.002] [Reference Citation Analysis]
7 Stein-thoeringer CK. GVHD prevention by personalized nutrition. Blood 2022;140:2190-2192. [DOI: 10.1182/blood.2022017857] [Reference Citation Analysis]
8 de Oliveira Andrade F, Verma V, Hilakivi‐clarke L. Maternal obesity and resistance to breast cancer treatments among offspring: Link to gut dysbiosis. Cancer Reports 2022. [DOI: 10.1002/cnr2.1752] [Reference Citation Analysis]
9 Pianko MJ. Impact of diet and antibiotics on gut microbiota and outcomes in patients with multiple myeloma treated with autologous hematopoietic stem cell transplantation. Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2148219] [Reference Citation Analysis]
10 Huang J, Mao Y. The impact of the microbiome in cancer: Targeting metabolism of cancer cells and host. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1029033] [Reference Citation Analysis]
11 Chen Z, Yue Z, Yang K, Li S. Nanomaterials: small particles show huge possibilities for cancer immunotherapy. J Nanobiotechnol 2022;20:484. [DOI: 10.1186/s12951-022-01692-3] [Reference Citation Analysis]
12 Zhang F, Yang P, Chen Y, Wang R, Liu B, Wang J, Yuan M, Zhang L. Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.1057492] [Reference Citation Analysis]
13 Agrawal MY, Gaikwad S, Srivastava S, Srivastava SK. Research Trend and Detailed Insights into the Molecular Mechanisms of Food Bioactive Compounds against Cancer: A Comprehensive Review with Special Emphasis on Probiotics. Cancers 2022;14:5482. [DOI: 10.3390/cancers14225482] [Reference Citation Analysis]
14 Boesch M, Horvath L, Baty F, Pircher A, Wolf D, Spahn S, Straussman R, Tilg H, Brutsche MH. Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. J Immunother Cancer 2022;10:e005401. [DOI: 10.1136/jitc-2022-005401] [Reference Citation Analysis]
15 Zhou C, Fang J. Cross communication of diet-microbiome-immune interactions in cancer immunotherapy. Cell Reports Medicine 2022;3:100806. [DOI: 10.1016/j.xcrm.2022.100806] [Reference Citation Analysis]
16 Pietrzak B, Tomela K, Olejnik-schmidt A, Galus Ł, Mackiewicz J, Kaczmarek M, Mackiewicz A, Schmidt M. A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition. Cancers 2022;14:5369. [DOI: 10.3390/cancers14215369] [Reference Citation Analysis]
17 Freed DM, Sommer J, Punturi N. Emerging target discovery and drug repurposing opportunities in chordoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1009193] [Reference Citation Analysis]
18 Muratore E, Leardini D, Baccelli F, Venturelli F, Prete A, Masetti R. Nutritional modulation of the gut microbiome in allogeneic hematopoietic stem cell transplantation recipients. Front Nutr 2022;9:993668. [DOI: 10.3389/fnut.2022.993668] [Reference Citation Analysis]
19 Sharma R, Diwan B, Sharma A, Witkowski JM. Emerging cellular senescence-centric understanding of immunological aging and its potential modulation through dietary bioactive components. Biogerontology 2022. [PMID: 36261747 DOI: 10.1007/s10522-022-09995-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Fernandes MR, Aggarwal P, Costa RGF, Cole AM, Trinchieri G. Targeting the gut microbiota for cancer therapy. Nat Rev Cancer 2022. [PMID: 36253536 DOI: 10.1038/s41568-022-00513-x] [Reference Citation Analysis]
21 Boucher E, Plazy C, Richard ML, Suau A, Mangin I, Cornet M, Aldebert D, Toussaint B, Hannani D. Inulin prebiotic reinforces host cancer immunosurveillance via γδ T cell activation.. [DOI: 10.1101/2022.10.13.512019] [Reference Citation Analysis]
22 Wang C. Research highlights in cancer immunotherapy from basic discovery to clinical trial. Holist Integ Oncol 2022;1:11. [DOI: 10.1007/s44178-022-00012-x] [Reference Citation Analysis]
23 McCormick BA, Inadomi JM. The Microbiome Modifies the Effect of Diet on Colorectal Cancer Incidence. Gastroenterology 2022;163:812-3. [PMID: 35940254 DOI: 10.1053/j.gastro.2022.07.066] [Reference Citation Analysis]
24 Daschner PJ, Ross S, Seifried H, Kumar A, Flores R. Nutrition and Microbiome Interactions in Human Cancer. Journal of the Academy of Nutrition and Dietetics 2022. [DOI: 10.1016/j.jand.2022.10.004] [Reference Citation Analysis]
25 Eaton SE, Kaczmarek J, Mahmood D, McDiarmid AM, Norarfan AN, Scott EG, Then CK, Tsui HY, Kiltie AE. Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients. Br J Cancer 2022. [PMID: 36175620 DOI: 10.1038/s41416-022-01980-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Tojjari A, Abushukair H, Saeed A. The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality. Cancers 2022;14:4641. [DOI: 10.3390/cancers14194641] [Reference Citation Analysis]
27 Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribeiro R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med 2022. [PMID: 36138151 DOI: 10.1038/s41591-022-01965-2] [Reference Citation Analysis]
28 Vu SH, Vetrivel P, Kim J, Lee MS. Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies. Int J Mol Sci 2022;23:10906. [PMID: 36142818 DOI: 10.3390/ijms231810906] [Reference Citation Analysis]
29 Adolph TE, Zhang J. Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts. Gut. [DOI: 10.1136/gutjnl-2021-326575] [Reference Citation Analysis]
30 Boesch M, Baty F, Kowatsch T, Wolf D, Früh M, Brutsche MH. Call for a holistic framework for cancer immunotherapy. Cancer. [DOI: 10.1002/cncr.34467] [Reference Citation Analysis]
31 Hu Y, Li Y, Satten GA, Hu Y. Testing microbiome associations with survival times at both the community and individual taxon levels. PLoS Comput Biol 2022;18:e1010509. [DOI: 10.1371/journal.pcbi.1010509] [Reference Citation Analysis]
32 Xu H, Cao C, Ren Y, Weng S, Liu L, Guo C, Wang L, Han X, Ren J, Liu Z. Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment. Front Immunol 2022;13:949490. [DOI: 10.3389/fimmu.2022.949490] [Reference Citation Analysis]
33 Andrews MC, Vasanthakumar A. Gut microbiota - a double-edged sword in cancer immunotherapy. Trends Cancer 2022:S2405-8033(22)00186-8. [PMID: 36088249 DOI: 10.1016/j.trecan.2022.08.003] [Reference Citation Analysis]
34 Li T, Liu T, Zhao Z, Pan Y, Xu X, Zhang Y, Zhan S, Zhou S, Zhu W, Guo H, Yang R. Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer. Front Immunol 2022;13:911325. [DOI: 10.3389/fimmu.2022.911325] [Reference Citation Analysis]
35 Griffin ME, Hang HC. Microbial mechanisms to improve immune checkpoint blockade responsiveness. Neoplasia 2022;31:100818. [PMID: 35816968 DOI: 10.1016/j.neo.2022.100818] [Reference Citation Analysis]
36 Lythgoe MP, Mullish BH, Frampton AE, Krell J. Polymorphic microbes: a new emerging hallmark of cancer. Trends Microbiol 2022:S0966-842X(22)00216-5. [PMID: 36058787 DOI: 10.1016/j.tim.2022.08.004] [Reference Citation Analysis]
37 Langouo Fontsa M, Padonou F, Willard-Gallo K. Biomarkers and immunotherapy: where are we? Curr Opin Oncol 2022;34:579-86. [PMID: 35943441 DOI: 10.1097/CCO.0000000000000891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Dohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, Iliev ID. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell 2022;185:3807-3822.e12. [DOI: 10.1016/j.cell.2022.09.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
39 Tan B, Liu YX, Tang H, Chen D, Xu Y, Chen MJ, Li Y, Wang MZ, Qian JM. Gut microbiota shed new light on the management of immune-related adverse events. Thorac Cancer 2022. [PMID: 36043345 DOI: 10.1111/1759-7714.14626] [Reference Citation Analysis]
40 Zhang L, Jin Q, Chai D, Kuang T, Li C, Guan Y, Liu L, Wang W, Deng W. The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors. Front Pharmacol 2022;13:937874. [DOI: 10.3389/fphar.2022.937874] [Reference Citation Analysis]
41 Gorgels KMF, van Alphen LB, van der Veer BMJW, Hackert VH, Hensels AYJ, Heijer CDJD, Dingemans J, Savelkoul PHM, Hoebe CJPA. Increased transmissibility of SARS-CoV-2 alpha variant (B.1.1.7) in children: three large primary school outbreaks revealed by whole genome sequencing in the Netherlands. BMC Infect Dis 2022;22:713. [PMID: 36038845 DOI: 10.1186/s12879-022-07623-9] [Reference Citation Analysis]
42 Murphy JF. The human microbiome and the tumor microenvironment. Explor Immunol 2022. [DOI: 10.37349/ei.2022.00069] [Reference Citation Analysis]
43 Yang S, Zhao S, Ye Y, Jia L, Lou Y. Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021). Front Immunol 2022;13:952546. [DOI: 10.3389/fimmu.2022.952546] [Reference Citation Analysis]
44 Genta S, Coburn B, Cescon DW, Spreafico A. Patient-derived cancer models: Valuable platforms for anticancer drug testing. Front Oncol 2022;12:976065. [DOI: 10.3389/fonc.2022.976065] [Reference Citation Analysis]
45 Schemczssen-graeff Z, Pileggi M. Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover. Front Genet 2022;13:921972. [DOI: 10.3389/fgene.2022.921972] [Reference Citation Analysis]
46 Zhou P, Hu Y, Wang X, Shen L, Liao X, Zhu Y, Yu J, Zhao F, Zhou Y, Shen H, Li J. Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy. Front Immunol 2022;13:877939. [DOI: 10.3389/fimmu.2022.877939] [Reference Citation Analysis]
47 Fang Y, Yang G, Yang J, Ren J, You L, Zhao Y. Human microbiota colonization and pancreatic ductal carcinoma. Crit Rev Microbiol 2022;:1-14. [PMID: 35924947 DOI: 10.1080/1040841X.2022.2080526] [Reference Citation Analysis]
48 White MG, Wargo JA. The Microbiome in Gastrointestinal Cancers. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2022.06.007] [Reference Citation Analysis]
49 Peiffer LB, White JR, Jones CB, Slottke RE, Ernst SE, Moran AE, Graff JN, Sfanos KS. Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab). Neoplasia 2022;32:100822. [PMID: 35908379 DOI: 10.1016/j.neo.2022.100822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 He X, Sun C, Fang J, Wu C, Zhang Y, Zhang X, Fang Y. In Vitro Colonic Fermentation Profiles and Microbial Responses of Cellulose Derivatives with Different Colloidal States. J Agric Food Chem 2022. [PMID: 35881531 DOI: 10.1021/acs.jafc.2c01721] [Reference Citation Analysis]
51 Aghamajidi A, Maleki Vareki S. The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer. Cancers 2022;14:3563. [DOI: 10.3390/cancers14153563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Inamura K, Hamada T, Bullman S, Ugai T, Yachida S, Ogino S. Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. Gut 2022:gutjnl-2022-327209. [PMID: 35820782 DOI: 10.1136/gutjnl-2022-327209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
53 Tonneau M, Nolin-lapalme A, Kazandjian S, Auclin E, Panasci J, Benlaifaoui M, Ponce M, Al-saleh A, Belkaid W, Naimi S, Mihalcioiu C, Watson I, Bouin M, Miller W, Hudson M, Wong MK, Pezo RC, Turcotte S, Bélanger K, Jamal R, Oster P, Velin D, Richard C, Messaoudene M, Elkrief A, Routy B. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. OncoImmunology 2022;11:2096535. [DOI: 10.1080/2162402x.2022.2096535] [Reference Citation Analysis]
54 Shah UA, Iyengar NM. Plant-Based and Ketogenic Diets As Diverging Paths to Address Cancer: A Review. JAMA Oncol 2022. [PMID: 35797039 DOI: 10.1001/jamaoncol.2022.1769] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Issa M, Tang J, Guo Y, Coss C, Mace TA, Bischof J, Phelps M, Presley CJ, Owen DH. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 2022;:1-14. [PMID: 35786142 DOI: 10.1080/14737140.2022.2094772] [Reference Citation Analysis]
56 Greathouse KL, Wyatt M, Johnson AJ, Toy EP, Khan JM, Dunn K, Clegg DJ, Reddy S. Diet-microbiome interactions in cancer treatment: Opportunities and challenges for precision nutrition in cancer. Neoplasia 2022;29:100800. [DOI: 10.1016/j.neo.2022.100800] [Reference Citation Analysis]
57 Ting NL, Lau HC, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut 2022;71:1412-25. [PMID: 35277453 DOI: 10.1136/gutjnl-2021-326264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
58 Takada K, Buti S, Bersanelli M, Shimokawa M, Takamori S, Matsubara T, Takenaka T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Nakanishi Y, Okamoto I, Pinato DJ, Cortellini A, Yoshizumi T. Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. Eur J Cancer 2022;172:199-208. [PMID: 35780526 DOI: 10.1016/j.ejca.2022.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Westheim AJF, Stoffels LM, Dubois LJ, van Bergenhenegouwen J, van Helvoort A, Langen RCJ, Shiri-sverdlov R, Theys J. Fatty Acids as a Tool to Boost Cancer Immunotherapy Efficacy. Front Nutr 2022;9:868436. [DOI: 10.3389/fnut.2022.868436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Shelkey E, Oommen D, Stirling ER, Soto-Pantoja DR, Cook KL, Lu Y, Votanopoulos KI, Soker S. Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy. Sci Rep 2022;12:9983. [PMID: 35705580 DOI: 10.1038/s41598-022-13930-7] [Reference Citation Analysis]
61 Guo Q, Qin H, Liu X, Zhang X, Chen Z, Qin T, Chang L, Zhang W. The Emerging Roles of Human Gut Microbiota in Gastrointestinal Cancer. Front Immunol 2022;13:915047. [DOI: 10.3389/fimmu.2022.915047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Hone Lopez S, Jalving M, Fehrmann RS, Nagengast WB, de Vries EG, de Haan JJ. The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment. Cancer Treatment Reviews 2022;107:102406. [DOI: 10.1016/j.ctrv.2022.102406] [Reference Citation Analysis]
63 Harris-Tryon TA, Grice EA. Microbiota and maintenance of skin barrier function. Science 2022;376:940-5. [PMID: 35617415 DOI: 10.1126/science.abo0693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
64 Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, Hayashi A, Jodai T, Akaike K, Anai M, Hamada S, Iyama S, Saruwatari K, Saeki S, Takahashi M, Ikeda T, Sakagami T. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. OncoImmunology 2022;11:2081010. [DOI: 10.1080/2162402x.2022.2081010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Yusuf K, Saha S, Umar S. Health Benefits of Dietary Fiber for the Management of Inflammatory Bowel Disease. Biomedicines 2022;10:1242. [DOI: 10.3390/biomedicines10061242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
66 Chang SC, Chiang HH, Liu CY, Li YJ, Lu CL, Lee YP, Huang CJ, Lai CL. Intestinal Mucosal Barrier Improvement with Prebiotics: Histological Evaluation of Longish Glucomannan Hydrolysates-Induced Innate T Lymphocyte Activities in Mice. Nutrients 2022;14:2220. [PMID: 35684019 DOI: 10.3390/nu14112220] [Reference Citation Analysis]
67 Yue Y, Hu Y. Extension of PERMANOVA to Testing the Mediation Effect of the Microbiome. Genes 2022;13:940. [DOI: 10.3390/genes13060940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Huo R, Zhang M, Zhang Y, Bai X, Zhang Y, Guo X. Effects of Oat Complex High-Fiber Formula Powder on the Composition of Intestinal Microbiota and Enzyme Activities in Mice Induced by a High-Fat Diet. Front Nutr 2022;9:871556. [DOI: 10.3389/fnut.2022.871556] [Reference Citation Analysis]
69 Nomura M. Association of the gut microbiome with cancer immunotherapy. Int J Clin Oncol 2022. [PMID: 35568746 DOI: 10.1007/s10147-022-02180-2] [Reference Citation Analysis]
70 Schummer P, Schilling B. How representative are data from global trials on programmed death-1 blockade in melanoma? Br J Dermatol 2022. [PMID: 35508326 DOI: 10.1111/bjd.21621] [Reference Citation Analysis]
71 Wei J, Hu M, Du H. Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment. Front Immunol 2022;13:845923. [PMID: 35281061 DOI: 10.3389/fimmu.2022.845923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Schmid S, Minnella EM, Pilon Y, Rokah M, Rayes R, Najmeh S, Cools-lartigue J, Ferri L, Mulder D, Sirois C, Owen S, Shieh B, Ofiara L, Wong A, Sud S, Baldini G, Carli F, Spicer J. Neoadjuvant prehabilitation therapy for locally advanced non-small-cell lung cancer: Optimizing outcomes throughout the trajectory of care. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.05.004] [Reference Citation Analysis]
73 Kim AJ, Hong DS, George GC. Dietary Influences On Symptomatic And Non-Symptomatic Toxicities During Cancer Treatment: A Narrative Review. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102408] [Reference Citation Analysis]
74 Chelvanambi M, Wargo JA. Trust your gut when it comes to driving CARs. Med 2022;3:281-3. [DOI: 10.1016/j.medj.2022.04.015] [Reference Citation Analysis]
75 Lim SA, Su W, Chapman NM, Chi H. Lipid metabolism in T cell signaling and function. Nat Chem Biol 2022;18:470-81. [PMID: 35484263 DOI: 10.1038/s41589-022-01017-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Yue Y, Hu Y. Extension of PERMANOVA to Testing the Mediation Effect of the Microbiome.. [DOI: 10.1101/2022.04.26.489586] [Reference Citation Analysis]
77 Kumar P, Brazel D, DeRogatis J, Valerin JBG, Whiteson K, Chow WA, Tinoco R, Moyers JT. The cure from within? a review of the microbiome and diet in melanoma. Cancer Metastasis Rev 2022. [PMID: 35474500 DOI: 10.1007/s10555-022-10029-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Mautner L, Hoyos M, Dangel A, Berger C, Ehrhardt A, Baiker A. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virol J 2022;19:76. [PMID: 35473640 DOI: 10.1186/s12985-022-01802-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
79 Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. Targeting the gut and tumor microbiota in cancer. Nat Med 2022;28:690-703. [PMID: 35440726 DOI: 10.1038/s41591-022-01779-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
80 Moerings BGJ, van Bergenhenegouwen J, Furber M, Abbring S, Schols HA, Witkamp RF, Govers C, Mes JJ. Dectin-1b activation by arabinoxylans induces trained immunity in human monocyte-derived macrophages. Int J Biol Macromol 2022:S0141-8130(22)00778-4. [PMID: 35447262 DOI: 10.1016/j.ijbiomac.2022.04.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Nogrady B. How gut reactions are shaping cancer treatment. Nature 2022;604:S1-3. [PMID: 35388199 DOI: 10.1038/d41586-022-00933-7] [Reference Citation Analysis]
82 Olekhnovich EI, Ivanov AB, Babkina AA, Sokolov AA, Ulyantsev VI, Fedorov DE, Ilina EN. Reproducible stool metagenomic biomarkers linked to the melanoma immunotherapy positive outcome.. [DOI: 10.1101/2022.04.01.486538] [Reference Citation Analysis]
83 Hersi F, Elgendy SM, Al Shamma SA, Atell RT, Sadiek O, Omar HA. Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.120573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol 2022. [PMID: 35354979 DOI: 10.1038/s41571-022-00620-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
85 Newsome RC, Gharaibeh RZ, Pierce CM, da Silva WV, Paul S, Hogue SR, Yu Q, Antonia S, Conejo-garcia JR, Robinson LA, Jobin C. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med 2022;14. [DOI: 10.1186/s13073-022-01037-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
86 Silveira MAD, Bilodeau S, Greten TF, Wang XW, Trinchieri G. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends Cancer 2022:S2405-8033(22)00045-0. [PMID: 35331674 DOI: 10.1016/j.trecan.2022.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Matson V, Gajewski TF. Dietary modulation of the gut microbiome as an immunoregulatory intervention. Cancer Cell 2022;40:246-8. [PMID: 35290783 DOI: 10.1016/j.ccell.2022.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Hoffmann M, Hayoz S, Özdemir BC. Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis. Biology 2022;11:422. [DOI: 10.3390/biology11030422] [Reference Citation Analysis]
89 Demleitner AF, Wolff AW, Erber J, Gebhardt F, Westenberg E, Winkler AS, Kolbe-Busch S, Chaberny IF, Lingor P. Best practice approaches to outpatient management of people living with Parkinson's disease during the COVID-19 pandemic. J Neural Transm (Vienna) 2022. [PMID: 35244753 DOI: 10.1007/s00702-022-02484-7] [Reference Citation Analysis]
90 Tu S, Pisters LL. Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies. Cancers 2022;14:1338. [DOI: 10.3390/cancers14051338] [Reference Citation Analysis]
91 Poonacha KNT, Villa TG, Notario V. The Interplay among Radiation Therapy, Antibiotics and the Microbiota: Impact on Cancer Treatment Outcomes. Antibiotics 2022;11:331. [DOI: 10.3390/antibiotics11030331] [Reference Citation Analysis]
92 Zitvogel L, Derosa L, Kroemer G. Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics. Cell Metab 2022;34:350-2. [PMID: 35235771 DOI: 10.1016/j.cmet.2022.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Meyer R. Ernährungsmedizin: Fasten und faserreiche Kost verbessern die Prognose. Deutsches Ärzteblatt Online 2022. [DOI: 10.3238/personko.2022.02.18.04] [Reference Citation Analysis]
94 Gorgels KMF, Dingemans J, van der Veer BMJW, Hackert V, Hensels AYJ, den Heijer CDJ, van Alphen LB, Savelkoul PHM, Hoebe CJPA. Linked nosocomial COVID-19 outbreak in three facilities for people with intellectual and developmental disabilities due to SARS-CoV-2 variant B.1.1.519 with spike mutation T478K in the Netherlands. BMC Infect Dis 2022;22:139. [PMID: 35139811 DOI: 10.1186/s12879-022-07121-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Bourgin M, Kepp O, Kroemer G. Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy. OncoImmunology 2022;11:2031500. [DOI: 10.1080/2162402x.2022.2031500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
96 Olesch C, Brüne B, Weigert A. Keep a Little Fire Burning-The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity. Int J Mol Sci 2022;23:1289. [PMID: 35163211 DOI: 10.3390/ijms23031289] [Reference Citation Analysis]
97 Grand’maison A, Kohrn R, Omole E, Shah M, Fiorica P, Sims J, Ohm JE. Genetic and environmental reprogramming of the sarcoma epigenome. Advances in Pharmacology 2022. [DOI: 10.1016/bs.apha.2022.10.001] [Reference Citation Analysis]